Compartilhar
Informação da revista
Vol. 46. Núm. S4.
HEMO 2024
Páginas S979 (outubro 2024)
Vol. 46. Núm. S4.
HEMO 2024
Páginas S979 (outubro 2024)
Acesso de texto completo
TARGETING PRC2 ENHANCES THE ANTITUMOR CYTOTOXIC CAPACITY OF ANTI-CD19 CAR-T CELLS AGAINST HEMATOLOGICAL MALIGNANCIES
Visitas
381
MLR Carvalhoa, CO Andradeb, MP Cabral-Piccina, GS Kinkera, GAF Vitielloa, L Abdob, RAG Cambuia, MH Bonaminob, TS Medinaa
a International Research Center, A.C.Camargo Cancer Center, São Paulo, SP, Brazil
b Cell and Gene Therapy Program – Research Coordination, Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil
Este item recebeu
Informação do artigo
Suplemento especial
Este artigo faz parte de:
Vol. 46. Núm S4

HEMO 2024

Mais dados

Chimeric Antigen Receptor (CAR) T cell therapy was adopted as a clinical modality for patients with relapsed/refractory hematological malignancies. Despite the clinical efficacy of CAR-T cell therapy, a considerable fraction of patients still relapses during the first months following CAR-T cell infusion. The limited CAR-T cell efficiency is thought to relate to epigenetic mechanisms involved in T-cell suppression and dysfunction. Here, screening of multiple epigenetic inhibitors revealed that targeting PRC2 consistently enhanced the cytotoxic/effector phenotype of CD8 T-cells. Notably, PRC2 inhibition promoted the differentiation of GZMB+ effector memory 19BBζ CAR-T cells and enhanced their antitumor activity both in vitro and in vivo. Consistent with their long-lasting antitumor activity, PRC2-inhibited 19BBζ CAR-T cells did not exhibit any signs of dysfunctionality/exhaustion. Furthermore, TCR restimulation along with PRC2 inhibition of patient-derived anti-CD19 CAR-T cells also induced the development of GZMB+ effector memory cells and elicited potent antitumor responses against CD19+ Daudi cells. In line with this, thegene signature derived from in-house PRC2-inhibited 19BBζ CAR-T cells was enriched in tisagenlecleucel (tisa-cel) BBζCAR-T cell therapy responders with large B-cell lymphoma. Collectively, our results demonstrated that targeting PRC2 may be a promising approach to enhance a functional effector program in CAR-T cells against hematological malignancies.

O texto completo está disponível em PDF
Baixar PDF
Idiomas
Hematology, Transfusion and Cell Therapy
Opções de artigo
Ferramentas